FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2135341119> ?p ?o ?g. }

• W2135341119 endingPage "136" @default.
• W2135341119 startingPage "133" @default.
• W2135341119 abstract "Therapeutic DeliveryVol. 2, No. 2 EditorialTargeted cancer therapy: dendritic cell metabolismJhanelle Gray & Alberto ChiapporiJhanelle GrayThoracic Oncology, Experimental Therapeutics, H Lee Moffitt Cancer Center & Research Institute, FL, USASearch for more papers by this author & Alberto Chiappori† Author for correspondenceThoracic Oncology, Experimental Therapeutics, H Lee Moffitt Cancer Center & Research Institute, 12902 Magnolia Drive, Tampa, FL 33612, USA. Search for more papers by this authorEmail the corresponding author at Alberto.chiappori@moffitt.orgPublished Online:28 Jan 2011https://doi.org/10.4155/tde.10.108AboutSectionsView ArticleView Full TextPDF/EPUB ToolsAdd to favoritesDownload CitationsTrack CitationsPermissionsReprints ShareShare onFacebookTwitterLinkedInReddit View articleKeywords: antigen-presenting celldendritic cellimmune responsemajor histocompatibility complexvaccinesBibliography1 Trombetta ES, Mellman I. Cell biology of antigen processing in vitro and in vivo. Annu. Rev. Immunol.23,975–1028 (2005).Crossref, Medline, CAS, Google Scholar2 Gabrilovich DI, Chen HL, Girgis KR et al. Production of vascular endothelial growth factor by human tumors inhibits the functional maturation of dendritic cells. Nat. Med.2(10),1096–1103 (1996).Crossref, Medline, CAS, Google Scholar3 Rosenberg SA. Identification of cancer antigens: impact on development of cancer immunotherapies. Cancer J. Sci. Am.6(Suppl. 3),200–207 (1995).Google Scholar4 Pittet MJ, Valmori D, Dunbar PR et al. High frequencies of naive Melan-A/MART-1-specific CD8+ T cells in a large proportion of human histocompatibility leukocyte antigen (HLA)-A2 individuals. J. Exp. Med.190(5),705–715 (1999).Crossref, Medline, CAS, Google Scholar5 Anichini A, Molla A, Mortarini R et al. An expanded peripheral T-cell population to a cytotoxic T lymphocyte (CTL)-defined, melanocyte-specific antigen in metastatic melanoma patients impacts on generation of peptide-specific CTLs but does not overcome tumor escape from immune surveillance in metastatic lesions. J. Exp. Med.190(5),651–667 (1999).Crossref, Medline, CAS, Google Scholar6 Jager E, Nagata Y, Gnjatic S et al. Monitoring CD8 T cell responses to NY-ESO-1: correlation of humoral and cellular immune responses. Proc. Natl Acad. Sci. USA, 97(9),4760–4765 (2000).Crossref, Medline, CAS, Google Scholar7 Huang M, Wang J, Lee P et al. Human nonsmall cell lung cancer cells express a type 2 cytokine pattern. Cancer Res.55(17),3847–3853 (1995).Medline, CAS, Google Scholar8 Herber DL, Cao W, Nefedova Y et al. Lipid accumulation and dendritic cell dysfunction in cancer. Nat. Med.16(8),880–886 (2010).Crossref, Medline, CAS, Google Scholar9 Stewart TJ, Abrams SI. How tumours escape mass destruction. Oncogene27(45),5894–5903 (2008).Crossref, Medline, CAS, Google Scholar10 Ramaswamy M, Cleland SY, Cruz AC, Siegel RM. Many checkpoints on the road to cell death: regulation of Fas–FasL interactions and Fas signaling in peripheral immune responses. Results Probl. Cell Differ.49,17–47 (2009).Crossref, Medline, CAS, Google Scholar11 Pirtskhalaishvili G, Shurin GV, Esche C et al. Cytokine-mediated protection of human dendritic cells from prostate cancer-induced apoptosis is regulated by the Bcl-2 family of proteins. Br. J Cancer83(4),506–513 (2000).Crossref, Medline, CAS, Google Scholar12 Esche C, Shurin GV, Kirkwood JM et al. Tumor necrosis factor-α-promoted expression of Bcl-2 and inhibition of mitochondrial cytochrome c release mediate resistance of mature dendritic cells to melanoma-induced apoptosis. Clin. Cancer Res.7(Suppl. 3),S974–S979 (2001).Google Scholar13 Kiertscher SM, Luo J, Dubinett SM, Roth MD. Tumors promote altered maturation and early apoptosis of monocyte-derived dendritic cells. J. Immunol.164(3),1269–1276 (2000).Crossref, Medline, CAS, Google Scholar14 Mach N, Dranoff G. Cytokine-secreting tumor cell vaccines. Curr. Opin. Immunol.12(5),571–575 (2000).Crossref, Medline, CAS, Google Scholar15 Nelson WG, Simons JW, Mikhak B et al. Cancer cells engineered to secrete granulocyte-macrophage colony-stimulating factor using ex vivo gene transfer as vaccines for the treatment of genitourinary malignancies. Cancer Chemother. Pharmacol.46(Suppl.),S67–S72 (2000).Crossref, Medline, CAS, Google Scholar16 Chen Q, Daniel V, Maher DW, Hersey P. Production of IL-10 by melanoma cells: examination of its role in immunosuppression mediated by melanoma. Int. J. Cancer56(5),755–760 (1994).Crossref, Medline, CAS, Google Scholar17 Smith DR, Kunkel SL, Burdick MD et al. Production of interleukin-10 by human bronchogenic carcinoma. Am. J. Pathol.145(1),18–25 (1994).Medline, CAS, Google Scholar18 Steinbrink K, Wolfl M, Jonuleit H, Knop J, Enk AH. Induction of tolerance by IL-10-treated dendritic cells. J. Immunol.159(10),4772–4780 (1997).Medline, CAS, Google Scholar19 Koch F, Stanzl U, Jennewein P et al. High level IL-12 production by murine dendritic cells: upregulation via MHC class II and CD40 molecules and downregulation by IL-4 and IL-10. J. Exp. Med.184(2),741–746 (1996).Crossref, Medline, CAS, Google Scholar20 Steinbrink K, Jonuleit H, Muller G, Schuler G, Knop J, Enk AH. Interleukin-10-treated human dendritic cells induce a melanoma-antigen-specific anergy in CD8+ T cells resulting in a failure to lyse tumor cells. Blood93(5),1634–1642 (1999).Crossref, Medline, CAS, Google Scholar21 Higano CS, Schellhammer PF, Small EJ et al. Integrated data from 2 randomized, double-blind, placebo-controlled, Phase iii trials of active cellular immunotherapy with sipuleucel-T in advanced prostate cancer. Cancer115(16),3670–3679 (2009).Crossref, Medline, CAS, Google Scholar22 Chiappori AA, Soliman H, Janssen WE, Antonia SJ, Gabrilovich DI. INGN-225: a dendritic cell-based p53 vaccine (Ad.p53-DC) in small cell lung cancer: observed association between immune response and enhanced chemotherapy effect. Expert Opin. Biol. Ther.10(6),983–991 (2010).Crossref, Medline, CAS, Google Scholar23 Small EJ, Sacks N, Nemunaitis J et al. Granulocyte macrophage colony-stimulating factor – secreting allogeneic cellular immunotherapy for hormone-refractory prostate cancer. Clin. Cancer Res.13(13),3883–3891 (2007).Crossref, Medline, CAS, Google Scholar24 Chiodoni C, Paglia P, Stoppacciaro A, Rodolfo M, Parenza M, Colombo MP. Dendritic cells infiltrating tumors cotransduced with granulocyte–macrophage colony-stimulating factor (GM-CSF) and CD40 ligand genes take up and present endogenous tumor-associated antigens, and prime naive mice for a cytotoxic T lymphocyte response. J. Exp. Med.190(1),125–133 (1999).Crossref, Medline, CAS, Google Scholar25 Dessureault S, Noyes D, Lee D et al. A Phase I trial using a universal GM-CSF-producing and CD40L-expressing bystander cell line (GM.CD40L) in the formulation of autologous tumor cell-based vaccines for cancer patients with stage IV disease. Ann. Surg. Oncol.14(2),869–884 (2007).Crossref, Medline, Google Scholar26 Terando A, Roessler B, Mule JJ. Chemokine gene modification of human dendritic cell-based tumor vaccines using a recombinant adenoviral vector. Cancer Gene Ther.11(3),165–173 (2004).Crossref, Medline, CAS, Google Scholar27 Hisada M, Yoshimoto T, Kamiya S et al. Synergistic antitumor effect by coexpression of chemokine CCL21/SLC and costimulatory molecule LIGHT. Cancer Gene Ther.11(4),280–288 (2004).Crossref, Medline, CAS, Google Scholar28 Hodi FS, O’Day SJ, McDermott DF et al. Improved survival with ipilimumab in patients with metastatic melanoma. N. Engl. J. Med.363(8),711–723 (2010).Crossref, Medline, CAS, Google Scholar29 Wheeler CJ, Das A, Liu G, Yu JS, Black KL. Clinical responsiveness of glioblastoma multiforme to chemotherapy after vaccination. Clin. Cancer Res.10(16),5316–5326 (2004).Crossref, Medline, CAS, Google Scholar30 Gribben JG, Ryan DP, Boyajian R et al. Unexpected association between induction of immunity to the universal tumor antigen CYP1B1 and response to next therapy. Clin. Cancer Res.11(12),4430–4436 (2005).Crossref, Medline, CAS, Google Scholar31 Radfar S, Wang Y, Khong HT. Activated CD4+ T cells dramatically enhance chemotherapeutic tumor responses in vitro and in vivo. J. Immunol.183(10),6800–6807 (2009).Crossref, Medline, CAS, Google Scholar32 Arlen PM, Gulley JL, Parker C et al. A randomized Phase II study of concurrent docetaxel plus vaccine versus vaccine alone in metastatic androgen-independent prostate cancer. Clin. Cancer Res.12(4),1260–1269 (2006).Crossref, Medline, CAS, Google Scholar33 Arlen PM, Madan RA, Hodge JW, Schlom J, Gulley JL. Combining vaccines with conventional therapies for cancer. Update Cancer Ther.2(1),33–39 (2007).Crossref, Medline, Google Scholar34 Schlom J, Arlen PM, Gulley JL. Cancer vaccines: moving beyond current paradigms. Clin. Cancer Res.13(13),3776–3782 (2007).Crossref, Medline, CAS, Google Scholar35 Gulley JL, Madan RA, Arlen PM. Enhancing efficacy of therapeutic vaccinations by combination with other modalities. Vaccine25(Suppl. 2),B89–B6 (2007).Crossref, Medline, CAS, Google Scholar36 Schlom J, Gulley JL, Arlen PM. Paradigm shifts in cancer vaccine therapy. Exp. Biol. Med. (Maywood)233(5),522–534 (2008).Crossref, Medline, CAS, Google Scholar101 Clinical trials.gov. A service of the US National Institute of Health. www.clinicaltrials.govGoogle ScholarFiguresReferencesRelatedDetails Vol. 2, No. 2 Follow us on social media for the latest updates Metrics Downloaded 129 times History Published online 28 January 2011 Published in print February 2011 Information© Future Medicine LtdKeywordsantigen-presenting celldendritic cellimmune responsemajor histocompatibility complexvaccinesAcknowledgementsThe authors thank Rasa Hamilton at the Moffitt Cancer Center for editorial assistance.Financial & competing interests disclosureThe authors have no relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript. This includes employment, consultancies, honoraria, stock ownership or options, expert testimony, grants or patents received or pending, or royalties. No writing assistance was utilized in the production of this manuscript.PDF download" @default.
• W2135341119 created "2016-06-24" @default.
• W2135341119 creator A5007121755 @default.
• W2135341119 creator A5080538468 @default.
• W2135341119 date "2011-02-01" @default.
• W2135341119 modified "2023-09-26" @default.
• W2135341119 title "Targeted cancer therapy: dendritic cell metabolism" @default.
• W2135341119 cites W1487917122 @default.
• W2135341119 cites W1958745508 @default.
• W2135341119 cites W1960538598 @default.
• W2135341119 cites W1979341960 @default.
• W2135341119 cites W1985752274 @default.
• W2135341119 cites W1986441039 @default.
• W2135341119 cites W1999304285 @default.
• W2135341119 cites W2008808864 @default.
• W2135341119 cites W2008840225 @default.
• W2135341119 cites W2022953715 @default.
• W2135341119 cites W2023456156 @default.
• W2135341119 cites W2029555062 @default.
• W2135341119 cites W2048084134 @default.
• W2135341119 cites W2057754694 @default.
• W2135341119 cites W2088571368 @default.
• W2135341119 cites W2097995306 @default.
• W2135341119 cites W2101591679 @default.
• W2135341119 cites W2112320456 @default.
• W2135341119 cites W2114964795 @default.
• W2135341119 cites W2125757318 @default.
• W2135341119 cites W2128519954 @default.
• W2135341119 cites W2135730659 @default.
• W2135341119 cites W2136071329 @default.
• W2135341119 cites W2142302700 @default.
• W2135341119 cites W2142721824 @default.
• W2135341119 cites W2144694610 @default.
• W2135341119 cites W2155020307 @default.
• W2135341119 cites W2157276434 @default.
• W2135341119 cites W2164658014 @default.
• W2135341119 cites W2167008563 @default.
• W2135341119 cites W2169258216 @default.
• W2135341119 cites W333385333 @default.
• W2135341119 doi "https://doi.org/10.4155/tde.10.108" @default.
• W2135341119 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/22833938" @default.
• W2135341119 hasPublicationYear "2011" @default.
• W2135341119 type Work @default.
• W2135341119 sameAs 2135341119 @default.
• W2135341119 citedByCount "0" @default.
• W2135341119 crossrefType "journal-article" @default.
• W2135341119 hasAuthorship W2135341119A5007121755 @default.
• W2135341119 hasAuthorship W2135341119A5080538468 @default.
• W2135341119 hasConcept C121608353 @default.
• W2135341119 hasConcept C126322002 @default.
• W2135341119 hasConcept C203014093 @default.
• W2135341119 hasConcept C2778170410 @default.
• W2135341119 hasConcept C2983331546 @default.
• W2135341119 hasConcept C2991704936 @default.
• W2135341119 hasConcept C502942594 @default.
• W2135341119 hasConcept C62231903 @default.
• W2135341119 hasConcept C71924100 @default.
• W2135341119 hasConcept C8891405 @default.
• W2135341119 hasConceptScore W2135341119C121608353 @default.
• W2135341119 hasConceptScore W2135341119C126322002 @default.
• W2135341119 hasConceptScore W2135341119C203014093 @default.
• W2135341119 hasConceptScore W2135341119C2778170410 @default.
• W2135341119 hasConceptScore W2135341119C2983331546 @default.
• W2135341119 hasConceptScore W2135341119C2991704936 @default.
• W2135341119 hasConceptScore W2135341119C502942594 @default.
• W2135341119 hasConceptScore W2135341119C62231903 @default.
• W2135341119 hasConceptScore W2135341119C71924100 @default.
• W2135341119 hasConceptScore W2135341119C8891405 @default.
• W2135341119 hasIssue "2" @default.
• W2135341119 hasLocation W21353411191 @default.
• W2135341119 hasLocation W21353411192 @default.
• W2135341119 hasOpenAccess W2135341119 @default.
• W2135341119 hasPrimaryLocation W21353411191 @default.
• W2135341119 hasRelatedWork W1534528611 @default.
• W2135341119 hasRelatedWork W2109763600 @default.
• W2135341119 hasRelatedWork W2344637265 @default.
• W2135341119 hasRelatedWork W2365364931 @default.
• W2135341119 hasRelatedWork W2418638721 @default.
• W2135341119 hasRelatedWork W2974335854 @default.
• W2135341119 hasRelatedWork W2984941165 @default.
• W2135341119 hasRelatedWork W3010846802 @default.
• W2135341119 hasRelatedWork W4210959948 @default.
• W2135341119 hasRelatedWork W4254320910 @default.
• W2135341119 hasVolume "2" @default.
• W2135341119 isParatext "false" @default.
• W2135341119 isRetracted "false" @default.
• W2135341119 magId "2135341119" @default.
• W2135341119 workType "article" @default.